Oliver Luxxe Assets LLC Has $3.69 Million Stock Position in HCA Healthcare, Inc. (NYSE:HCA)

Oliver Luxxe Assets LLC grew its stake in shares of HCA Healthcare, Inc. (NYSE:HCA) by 2.9% in the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 12,284 shares of the company’s stock after buying an additional 344 shares during the period. Oliver Luxxe Assets LLC’s holdings in HCA Healthcare were worth $3,687,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. FMR LLC raised its position in HCA Healthcare by 322.3% in the third quarter. FMR LLC now owns 3,141,769 shares of the company’s stock worth $1,276,909,000 after purchasing an additional 2,397,883 shares in the last quarter. Darsana Capital Partners LP raised its stake in shares of HCA Healthcare by 53.3% in the second quarter. Darsana Capital Partners LP now owns 1,150,000 shares of the company’s stock valued at $369,472,000 after acquiring an additional 400,000 shares during the last quarter. Meritage Group LP bought a new stake in HCA Healthcare during the 3rd quarter worth approximately $150,548,000. Holocene Advisors LP boosted its stake in HCA Healthcare by 210.6% in the third quarter. Holocene Advisors LP now owns 306,796 shares of the company’s stock worth $124,691,000 after purchasing an additional 208,015 shares in the last quarter. Finally, Nordea Investment Management AB increased its stake in shares of HCA Healthcare by 29.7% in the fourth quarter. Nordea Investment Management AB now owns 843,764 shares of the company’s stock valued at $253,020,000 after buying an additional 193,075 shares in the last quarter. 62.73% of the stock is currently owned by institutional investors.

HCA Healthcare Stock Down 0.0 %

NYSE HCA traded down $0.09 during trading hours on Monday, hitting $296.61. 854,034 shares of the company traded hands, compared to its average volume of 1,008,546. The business’s 50-day moving average is $326.93 and its 200-day moving average is $354.99. HCA Healthcare, Inc. has a twelve month low of $276.50 and a twelve month high of $417.14. The stock has a market capitalization of $75.13 billion, a price-to-earnings ratio of 13.32, a P/E/G ratio of 1.21 and a beta of 1.64. The company has a debt-to-equity ratio of 48.71, a quick ratio of 1.00 and a current ratio of 1.12.

HCA Healthcare Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, December 27th. Investors of record on Friday, December 13th were issued a dividend of $0.66 per share. This represents a $2.64 annualized dividend and a dividend yield of 0.89%. The ex-dividend date of this dividend was Friday, December 13th. HCA Healthcare’s payout ratio is 11.85%.

Insiders Place Their Bets

In other news, SVP Phillip G. Billington sold 3,897 shares of the stock in a transaction on Thursday, November 14th. The stock was sold at an average price of $350.00, for a total transaction of $1,363,950.00. Following the sale, the senior vice president now directly owns 52,702 shares of the company’s stock, valued at approximately $18,445,700. This represents a 6.89 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Erol R. Akdamar sold 2,900 shares of the company’s stock in a transaction dated Thursday, November 14th. The stock was sold at an average price of $353.00, for a total transaction of $1,023,700.00. Following the sale, the insider now directly owns 6,843 shares of the company’s stock, valued at $2,415,579. This represents a 29.76 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 1.60% of the company’s stock.

Analyst Ratings Changes

Several research firms have weighed in on HCA. Truist Financial lowered their price objective on shares of HCA Healthcare from $430.00 to $390.00 and set a “buy” rating for the company in a research report on Monday. StockNews.com downgraded HCA Healthcare from a “strong-buy” rating to a “buy” rating in a report on Monday, November 4th. KeyCorp cut their price target on HCA Healthcare from $475.00 to $420.00 and set an “overweight” rating on the stock in a research note on Monday, October 28th. JPMorgan Chase & Co. restated a “neutral” rating and set a $380.00 target price on shares of HCA Healthcare in a research report on Tuesday, December 17th. Finally, Raymond James lowered shares of HCA Healthcare from an “outperform” rating to a “market perform” rating in a report on Friday, November 22nd. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, twelve have given a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $388.60.

HCA Healthcare Company Profile

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.